Zobrazeno 1 - 10
of 14
pro vyhledávání: ''
Autor:
PharmD, Susamma M Wilson, Eduardo Bruera, Aline Rozman de Moraes, Zhanni Lu, Sriram Yennurajalingam, John M Najera, David Hui, Joseph Arthur, Tonya Edwards, Kristy Nguyen, Shirley Darlene Ethridge, Michal J Kubiak, Jimin Wu, Suresh K. Reddy, Yu Qian, Elif Erdogan, Saima Rashid, Manju P Joy, Leela Kuriakose, Jimi S Malik
Publikováno v:
JAMA Oncol
IMPORTANCE: One of the main aims of research on nonmedical opioid use (NMOU) is to reduce the frequency of NMOU behaviors through interventions such as universal screening, reduced opioid exposure, and more intense follow-up of patients with elevated
Autor:
N. Lynn Henry, Robert A. Bagramian, Mark M. Schubert, Amy K. Darke, Shaker R. Dakhil, Danika L. Lew, Catherine Van Poznak, James L. Wade, Dawn L. Hershman, Justin D. Floyd, Carol M. Moinpour, Michael J. Fisch, Joseph M. Unger, Lisa Hansen, Julie R. Gralow
Publikováno v:
JAMA Oncol
Importance Osteonecrosis of the jaw (ONJ) affects patients with cancer and metastatic bone disease (MBD) treated with bone-modifying agents (BMAs), yet the true incidence is unknown. Objective To define the cumulative incidence of ONJ at 3 years in p
Publikováno v:
JAMA Oncol
This study analyzes the incidence of opioid-associated deaths in cancer survivors vs the general population in the US from 2006 through 2016 using National Center for Health Statistics death certificate data.
Autor:
Ethan Basch, Antonia V. Bennett, Gita Thanarajasingam, Gisela Schwab, Lauren J. Rogak, Howard I. Scher, Amylou C. Dueck, Gina L. Mazza, Aaron Weitzman
Publikováno v:
JAMA Oncol
IMPORTANCE: Standard adverse event (AE) reporting in oncology clinical trials has historically relied on clinician grading, which prior research has shown can lead to underestimation of rates of symptomatic AEs. Industry sponsors are beginning to imp
Publikováno v:
JAMA Network Open
Key Points Question Is peer influence associated with physician adoption of new cancer therapies? Findings In this cohort study of 44 012 Medicare beneficiaries with cancer treated by 3261 oncologists, use of bevacizumab in 2007 to 2010 was greater a
Publikováno v:
JAMA Network Open
Aspirin use has been associated with reduced risk of cancer mortality, particularly of the colorectum. However, aspirin efficacy may be influenced by biological characteristics, such as obesity and age. With the increasing prevalence of obesity and c
Autor:
Chul Kim, Michael R. Cook
Publikováno v:
JAMA Oncology. 5:1049
Importance Patients with HIV infection are at increased risk for cancer. Cancer is the leading cause of death among non–AIDS-defining illnesses in these patients. Immune checkpoint inhibitor (ICI) therapy has transformed the treatment of cancer. Ho
Autor:
James A. Tulsky, Isaac S. Chua, Charlotta Lindvall, Emanuele Mazzola, Charles A. Coey, Kate Brizzi, Richard E. Leiter
Publikováno v:
JAMA Oncology. 5:734
This study evaluates the patient demographics and clinical characteristics of 14 095 opioid-related hospitalizations from the US National Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP).
Autor:
Andrea M. Austin, Gabriel A. Brooks, Anna N. A. Tosteson, Deborah Schrag, Hajime Uno, Konstantin H. Dragnev
Publikováno v:
JAMA Network Open
Key Points Question Does the risk of hospitalization among elderly patients receiving chemotherapy for metastatic, nonsquamous, non–small cell lung cancer vary by chemotherapy regimen? Findings In a cohort study of 2182 propensity-matched Medicare
Autor:
Eric K. Nakakura
Publikováno v:
JAMA Surgery. 153:67
This population-based cohort study evaluates the association of primary tumor site with mortality among patients receiving systemic chemotherapy and biologic therapy for metastatic colorectal cancer.